The development of treatments for NASH poses several challenges. Firstly, NASH has various underlying factors and patients' responses to drugs can differ, making the development process complex. Additionally, obtaining liver tissue samples for clinical trials can be difficult. Assessing the severity of NASH is subjective, which has been a concern in some clinical studies. Pharmaceutical companie..